Immunohistochemical Study of the Expressed Cluster Differentiation Markers Proteins Type 20 And 56 in Breast Tissues from a Group of Iraqi Patients with Breast Cancers

Q: What biomarkers are assessed in this immunohistochemical study?

The study measures CD20, a B-cell surface marker, and CD56, an NK-cell surface marker, on infiltrative lymphocytic subpopulations in breast tissues.

Q: How were tissue samples selected for the analysis?

One hundred and seventy-five archived breast tissue samples were included: invasive breast cancer, benign breast tumor biopsies, and apparently normal healthy breast tissues as the control group.

Q: What were the main findings for CD20 and CD56 expression?

CD20-positive reactions were observed more frequently in both invasive cancers and benign tumors than in controls, with significant differences versus controls. CD56 reactions appeared in subsets of cancer and benign tissues but showed no presence in control tissues, with no significant differences across groups.

Sep 24, 2026

Uploaded by Levi

Immunohistochemical analysis evaluates tumor-infiltrating lymphocyte involvement in breast cancer by quantifying CD20 (B-cell) and CD56 (NK-cell) surface biomarkers on lymphocytic subpopulations in Iraqi female patients. A retrospective cohort of 175 archived breast tissue samples includes invasive cancer, benign tumors, and healthy controls. CD20 detection is reported in 53% of invasive cancers versus 48% in benign tumors and 32% in controls, with significant group differences versus controls. CD56 reactions occur in 14% of cancers and 16% of benign tumors, with no control positivity.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages8

Reading Time20 min

AccessFree to download

Abstract

Introduction

RESEARCH ARTICLE Editorial Process: Submission:07/12/2023 Acceptance:10/24/2023 Immunohistochemical Study of the Expressed Cluster Differentiation Markers Proteins Type 20 And 56 in Breast Tissues from a Group of Iraqi Patients with Breast Cancers Sarmad M H Zeiny1 *, Saad Hasan Mohammed Ali2 Abstract Background: Tumor-infiltrating lymphocytes (TIL) are important immunological components in response to cancers. Patients with higher numbers ofTIL in breast cancerous tissues, comprising T-cytotoxic and T – helper cells along with B-and rare natural killer (NK) cells, have more favorable clinical outcomes. Objective: To analyze the rate of the expressed surface biomarker proteins of CD20-B cells and CD56-NK cells on the infiltrative lymphocytic subpopulations in a group of breast tumorous tissues (invasive and benign) from female patients in Iraq and explore the relations to the grade of the invasive breast cancerous tissues. Patients and methods: One hundred and 75 archived breast tissues were enrolled in this retrospective research: 100 archived breast from female patients with invasive breast cancers (BC) [20 well differentiated BC tissues; 48 moderately differentiated BC and 32 poorly differentiated BC tissues]; 50 tissue biopsies from female patients with benign breast tumors and 25 apparently normal individuals with healthy breast tissues (included as the control group for this study). Immunohistochemistry was achieved for the detection of the expressed surface biomarker proteins related to B cell CD20 and NK cell CD56 present on the infiltrative lymphocytic subpopulations in breast tissues by using specific primary antibodies for these proteins via utilizing an immune-enzymatic antigen detection system. Results: The detection ofIHC reactions for the expressed B cell CD20-cell surface ( CD) biomarker proteins were observed in 53 out of 100 (53.0%) BC tissues, and in 24 out of 50 (48.0%) benign breast tumorous tissues, while CD20-positive cell surface markers was detected in apparently healthy breast tissues ofthe control group in a percentage of 32.0%(8 out of 25 tissues) . Statistical significant differences (P<0.05) between both groups of malignant and benign breast tumors and the control group were found. However, between breast malignant and benign tumor groups, no significant difference was found ( p >0.05) . Detection of CD56-IHC reactions revealed in 14%(14 out of 100 BC tissues), in 16%(8 out of 50 benign breast tissues) and none of control breast tissues revealed CD56-IHC reactions. Among all the enrolled groups, no significant differences (P>0.05) were detected. Conclusions: The observed significant rates that showed highly significant differences between both studied groups of breast malignant and benign tumor in comparison to the control group indicate that the CD20-positive infiltrative B cell-lymphocytic subpopulations might contributed in the defense against these subsets of benign and malignant breast tumors. However, the observed rates of NK cell CD56 present on the lymphocytic subpopulations infiltrating the examined malignant and benign breast tumorous tissues seeming to play irrelevant roles in the defense against these studied breast tumor groups. Keywords: Breast cancers-benign breast tumors-CD56-CD20-NK cells-B lymphocytes-IHC Asian Pac J Cancer Prev, 24 (10), 3621-3628 Introduction Globally, breast cancer is the most prevalent cancer. World-wide, 2.3 million women in 2020 as well as 7.8 million were diagnosed in the past 5 years to have breast cancers and reporting 685,000 deaths from such cancers (WHO, 2021) . The incidence of female breast cancers continued to have a slow increase (annually as 0.5%) from 2014 through the year of 2018. In 2022, death was estimated to comprise a total of 43,250 women as well as 530 men because of their breast cancers (ASC, 2021) . A rare, highly aggressive, inflammatory breast cancer (IBC), is still poorly understood although it accounts for < 3

FAQs

What biomarkers are assessed in this immunohistochemical study?

The study measures CD20, a B-cell surface marker, and CD56, an NK-cell surface marker, on infiltrative lymphocytic subpopulations in breast tissues.

How were tissue samples selected for the analysis?

One hundred and seventy-five archived breast tissue samples were included: invasive breast cancer, benign breast tumor biopsies, and apparently normal healthy breast tissues as the control group.

What were the main findings for CD20 and CD56 expression?

CD20-positive reactions were observed more frequently in both invasive cancers and benign tumors than in controls, with significant differences versus controls. CD56 reactions appeared in subsets of cancer and benign tissues but showed no presence in control tissues, with no significant differences across groups.

Sep 24, 2026

Uploaded by Levi